Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Phosphodiesterase inhibition in cognitive decline.

García-Barroso C, Ugarte A, Martínez M, Rico AJ, Lanciego JL, Franco R, Oyarzabal J, Cuadrado-Tejedor M, García-Osta A.

J Alzheimers Dis. 2014;42 Suppl 4:S561-73. doi: 10.3233/JAD-141341. Review.

PMID:
25125473
2.

PDE inhibition and cognition enhancement.

Blokland A, Menniti FS, Prickaerts J.

Expert Opin Ther Pat. 2012 Apr;22(4):349-54. doi: 10.1517/13543776.2012.674514. Review. No abstract available.

PMID:
22475506
3.
4.

The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey.

Smith SM, Uslaner JM, Cox CD, Huszar SL, Cannon CE, Vardigan JD, Eddins D, Toolan DM, Kandebo M, Yao L, Raheem IT, Schreier JD, Breslin MJ, Coleman PJ, Renger JJ.

Neuropharmacology. 2013 Jan;64:215-23. doi: 10.1016/j.neuropharm.2012.06.013. Epub 2012 Jun 27.

PMID:
22750078
6.

Selective phosphodiesterase inhibitors: a promising target for cognition enhancement.

Reneerkens OA, Rutten K, Steinbusch HW, Blokland A, Prickaerts J.

Psychopharmacology (Berl). 2009 Jan;202(1-3):419-43. doi: 10.1007/s00213-008-1273-x. Epub 2008 Aug 16. Review.

7.

PDE10 inhibition increases GluA1 and CREB phosphorylation and improves spatial and recognition memories in a Huntington's disease mouse model.

Giralt A, Saavedra A, Carretón O, Arumí H, Tyebji S, Alberch J, Pérez-Navarro E.

Hippocampus. 2013 Aug;23(8):684-95. doi: 10.1002/hipo.22128. Epub 2013 Apr 29.

PMID:
23576401
8.

Phosphodiesterases in the central nervous system: implications in mood and cognitive disorders.

Xu Y, Zhang HT, O'Donnell JM.

Handb Exp Pharmacol. 2011;(204):447-85. doi: 10.1007/978-3-642-17969-3_19. Review.

PMID:
21695652
9.

Targeting cancer with phosphodiesterase inhibitors.

Savai R, Pullamsetti SS, Banat GA, Weissmann N, Ghofrani HA, Grimminger F, Schermuly RT.

Expert Opin Investig Drugs. 2010 Jan;19(1):117-31. doi: 10.1517/13543780903485642. Review.

PMID:
20001559
10.

Phosphodiesterase inhibitors as potential cognition enhancing agents.

Schmidt CJ.

Curr Top Med Chem. 2010;10(2):222-30. Review.

PMID:
20166957
11.

Phosphodiesterase inhibitors for cognitive enhancement.

Rose GM, Hopper A, De Vivo M, Tehim A.

Curr Pharm Des. 2005;11(26):3329-34. Review.

PMID:
16250839
12.

Phosphodiesterase: an interface connecting cognitive deficits to neuropsychiatric and neurodegenerative diseases.

Wang ZZ, Zhang Y, Zhang HT, Li YF.

Curr Pharm Des. 2015;21(3):303-16. Review.

PMID:
25159069
13.

Chronic phosphodiesterase type 2 inhibition improves memory in the APPswe/PS1dE9 mouse model of Alzheimer's disease.

Sierksma AS, Rutten K, Sydlik S, Rostamian S, Steinbusch HW, van den Hove DL, Prickaerts J.

Neuropharmacology. 2013 Jan;64:124-36. doi: 10.1016/j.neuropharm.2012.06.048. Epub 2012 Jul 4.

PMID:
22771768
14.

The Phosphodiesterase 10A Selective Inhibitor TAK-063 Improves Cognitive Functions Associated with Schizophrenia in Rodent Models.

Shiraishi E, Suzuki K, Harada A, Suzuki N, Kimura H.

J Pharmacol Exp Ther. 2016 Mar;356(3):587-95. doi: 10.1124/jpet.115.230482. Epub 2015 Dec 16.

PMID:
26675680
15.

Update on phosphodiesterase (PDE) isoenzymes as pharmacologic targets in urology: present and future.

Uckert S, Hedlund P, Andersson KE, Truss MC, Jonas U, Stief CG.

Eur Urol. 2006 Dec;50(6):1194-207; discussion 1207. Epub 2006 Jun 6. Review.

PMID:
16815627
16.

Phosphodiesterase type 5 inhibition improves early memory consolidation of object information.

Prickaerts J, Sik A, van Staveren WC, Koopmans G, Steinbusch HW, van der Staay FJ, de Vente J, Blokland A.

Neurochem Int. 2004 Nov;45(6):915-28. Review.

PMID:
15312986
17.

PDE and cognitive processing: beyond the memory domain.

Heckman PR, Blokland A, Ramaekers J, Prickaerts J.

Neurobiol Learn Mem. 2015 Mar;119:108-22. doi: 10.1016/j.nlm.2014.10.011. Epub 2014 Nov 13. Review.

PMID:
25464010
18.

Phosphodiesterase 10A inhibition is associated with locomotor and cognitive deficits and increased anxiety in mice.

Hebb AL, Robertson HA, Denovan-Wright EM.

Eur Neuropsychopharmacol. 2008 May;18(5):339-63. Epub 2007 Oct 29.

PMID:
17913473
19.

Phosphodiesterase inhibitors enhance object memory independent of cerebral blood flow and glucose utilization in rats.

Rutten K, Van Donkelaar EL, Ferrington L, Blokland A, Bollen E, Steinbusch HW, Kelly PA, Prickaerts JH.

Neuropsychopharmacology. 2009 Jul;34(8):1914-25. doi: 10.1038/npp.2009.24. Epub 2009 Mar 4.

20.

Phosphodiesterases as therapeutic targets for Huntington's disease.

Fusco FR, Giampà C.

Curr Pharm Des. 2015;21(3):365-77. Review.

PMID:
25159076
Items per page

Supplemental Content

Write to the Help Desk